

**To:**  
The General Manager  
Pakistan Stock Exchange Limited  
Stock Exchange Building  
Karachi

**Subject: MATERIAL INFORMATION SIGNING OF MOU WITH TOFFLON THE TECH GIANT OF CHINA**

In accordance with Clause 5.6.1(a) of PSX Regulations and Section 96 of the Securities Act, 2015, we hereby inform you of the following material information.

The Board of Directors and the management of LIVEN Pharma Limited ("the Company") are pleased to inform that the Company has entered into a Memorandum of Understanding (MOU) with TOFFLON Science and Technology Group Co., Ltd., People's Republic of China ("TOFFLON"), one of the world's leading and CHINA's Tech Giant and manufacturers of pharmaceutical, biotechnology and aseptic processing plants, production systems and advanced manufacturing technologies.

The Memorandum of Understanding was formally executed on behalf of TOFFLON by Mr. Michael Chang, Senior Vice President, TOFFLON Science and Technology Group and by Mr. Kaashif Hussain CEO on behalf of LIVEN Pharma Limited in a very auspicious ceremony in Shanghai on the occasion of CPHI in front of the International audience marking a new era of recognition not only for LIVEN but for Pakistan also and reflecting the strategic importance attached by TOFFLON to this collaboration and underscoring the mutual commitment of both organizations towards establishing a long-term partnership.

This strategic milestone forms an integral part of LIVEN Pharma Limited's Vision 2030, under which the Company aims to transform itself into a fully integrated pharmaceutical and biotechnology enterprise through the acquisition of world-class manufacturing technologies, localization of advanced production capabilities, and development of Pakistan's high-value pharmaceutical and biological manufacturing infrastructure.

The Company believes this MOU represents a landmark achievement for Pakistan's pharmaceutical industry. To the best of the Company's knowledge and belief, LIVEN Pharma Limited has become the first Pakistani pharmaceutical company to secure the willingness of a globally renowned Chinese pharmaceutical technology group to formally pursue investment and strategic industrial collaboration within Pakistan's pharmaceutical and biological manufacturing sector through such a comprehensive framework arrangement.

This understanding reflects growing international confidence in Pakistan's pharmaceutical industry and demonstrates LIVEN Pharma Limited's commitment to attracting foreign technology, foreign direct investment, advanced manufacturing capabilities and global expertise into the country.



The collaboration is expected to accelerate the Company's long-term strategic objectives under Vision 2030, including the localization of sophisticated pharmaceutical and biotechnology manufacturing, enhancement of export competitiveness, strengthening of national healthcare infrastructure, and reduction in reliance on imported high-value biological products.


The Memorandum of Understanding establishes the framework for future cooperation. Any definitive agreements, investment decisions, capital commitments or projects arising therefrom shall remain subject to completion of technical evaluations, commercial negotiations, regulatory approvals, corporate approvals and execution of definitive agreements, where applicable. The Company shall keep the Exchange informed of any further material developments in accordance with the applicable regulatory requirements.

This intimation is being made to ensure transparency and to keep the Exchange and stakeholders informed of the ongoing deliberations. We emphasize that this communication should not be construed as a confirmation of any definitive agreement, arrangement, or commitment at this point in time.

You may please inform the TRE Certificate Holders of the Exchange accordingly.

For and on behalf of

Kaashif Hussain  
CEO  
LIVEN Pharma Limited



Tuesday, June 23, 2026

